A phase 2a trial was recently conducted to study the efficacy and safety of fezakinumab in adults with moderate-to-severe atopic dermatitis (AD) that was inadequately controlled by conventional treatments. Improvements were observed and fezakinumab was well-tolerated.
Read the study at the Journal of the American Academy of Dermatology. (Open Access)
Work Cited: Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial Guttman-Yassky, Emma et al., Journal of the American Academy of Dermatology, Volume 7, Issue 5, 872-881.e6